Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedHepatitis BHepatitis CHepatitis DHepatitis EAIDS

Hepatitis B and C Prevention, Screening, and Diagnostic Services at HIV Treatment Sites: International Epidemiology Databases to Evaluate AIDS.

Journal of acquired immune deficiency syndromes (1999)·

Kuniholm MH, Murenzi G, Samala N, Yunihastuti E, Wandeler G, Kim HN, Plaisy MK, Perazzo H, Twizere C, Odhiambo F, Bopage R, Muula G, Lo Re V 3rd, Minga A, López-Iñiguez A, Nsonde DM, Kasozi C, Wati DK, Fox MP, Kirk GD, Messou E, Cesar C, Ebasone PV, Byakwaga H, Ross J, Chimbetete C, Yendewa GA, Jaquet A, Succi RCM, Maruri F, Brazier E

DOI
10.1097/qai.0000000000003896
PMID
42086340
PMCID
OpenAlex
Study type
Journal article
Publisher
Publisher unavailable
Article type
journal-article
Integrity
current

Why this research matters now

Findings point to gaps in HBV and HCV service availability at HIV treatment sites, particularly rural sites, relevant to efforts to address these infections among people receiving HIV care.

01

Structured evidence summary

Research question

The study examined the availability of HBV and HCV prevention, screening, and diagnostic services at HIV treatment sites participating in a multinational network.

Study design

Cross-sectional survey of HIV treatment centers across 7 IeDEA regions using 2023 service-delivery data, with multivariable logistic regression to test associations between site characteristics and service availability.

Population and setting

A total of 204 HIV treatment sites within the IeDEA network across 7 global regions, including sites serving predominantly urban or rural populations.

Main findings

On-site HBV vaccination was reported at 67.7% of sites; HBV and HCV screening at enrollment at 72.1% and 50%, respectively; and on-site HBsAg, HBV DNA, HCV antibody, and HCV RNA testing at 77%, 47.6%, 61.8%, and 44.6%, respectively. Sites serving predominantly rural (vs. urban) populations had lower odds of on-site HBV DNA, HCV antibody, and HCV RNA testing.

Public-health relevance

Findings point to gaps in HBV and HCV service availability at HIV treatment sites, particularly rural sites, relevant to efforts to address these infections among people receiving HIV care.

Important limitations

This summary is limited to the supplied single-article abstract/metadata and requires the original paper for decision-grade interpretation; explicit limitations beyond the cross-sectional, self-reported survey design were not provided in the abstract.

GIDS interpretation

The paper is catalogued under hepatitis and HIV-related topics including diagnostics, treatment, and vaccination, making it discoverable for editors seeking evidence on hepatitis service integration in HIV care settings; no connection to a live surveillance signal is made.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 15 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseabout diseaseabout diseaseabout diseaseabout diseaseaddresses topicaddresses topicaddresses topicevaluates interventionevaluates interventionevaluates interventionhas pathogen typestudied population settingstudies pathogenuses study design